BioNTech announces the inauguration of a messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda. The inauguration coincides with the opening of the first production unit, named BioNTainer. The Group’s aim is to “help build a sustainable and resilient African vaccine ecosystem and support equitable access to new medicines worldwide”. The site could become the continent’s first commercial-scale mRNA manufacturing plant.
BioNTech plans to complete all site buildings and begin training specialized personnel in 2024, with experimental mRNA production to be launched in 2025.